FDA thumbs-up completes automated acute hepatitis panel for Bayer:
This article was originally published in Clinica
Bayer Diagnostics claims it has scored a US first in automated acute hepatitis testing, after gaining FDA clearance to add HBsAg and HBsAg confirmatory assays to the existing six hepatitis tests available on its Advia Centaur immunoassay system. With the clearance, Bayer offers the industry's only complete, FDA-approved automated panel for acute hepatitis testing including assays for HBsAg, HCV, anti-HBc IgM and anti-HAV IgM, said the Tarrytown, New York-based firm. As for other assays on the panel, which can also diagnose and confirm chronic hepatitis B infections, they comprise anti-HBs, anti-HBc total and anti-HAV total.
You may also be interested in...
Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar
On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.